Basement membrane and growth factor gene expression in normal and diabetic human retinas

References

• Ljubimov AV, Burgeson RE, Butkowski RJ, Couchman JR, Zardi L, Ninomiya Y, Sado Y, Huang Z, Nesburn AB, Kenney MC. Basement membrane abnormalities in human eyes with diabetic retinopathy. J Histochem Cytochem. 1996;44:1469–1479.
   PubMed Web of Science ®Google Scholar
• Williamson JR, Tilton RG, Chang K, Kilo C. Base-ment membrane abnormalities in diabetes mellitus: re-lationship to clinical microangiopathy. Diabetes/Metabo-lism Revs. 1988;4:339–370.
   PubMed Web of Science ®Google Scholar
• Osterby R. Basement membrane morphology in diabe-tes mellitus. In: Rifkin H, Porte D, Jr. Diabetes Melli-tus. Theory and Practice, 4th ed. New York-Amsterdam-London: Elsevier; 1990:220–233.
   Google Scholar
• Grant MB, Ellis EA, Caballero S, Mames RN. Plasmi-nogen activator inhibitor-1 overexpression in nonpro-liferative diabetic retinopathy. Exp Eye Res. 1996;63:233–244.
   PubMed Web of Science ®Google Scholar
• Sivalingam A, Kenney J, Brown GC, Benson WE, Donoso L. Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retino-pathy. Arch Ophthalmol. 1990;108:869–872.
   Google Scholar
• Grant M, Russell B, Fitzgerald C, Merimee TJ. Insu-lin-like growth factors in vitreous. Studies in control and diabetic subjects with neovascularization. Diabe-tes 1986;35:416–420.
   Google Scholar
• Meyer-Schwickerath R, Pfeiffer A, Blum WF, Freyberger H, Klein M, Lösche C, Röllmann R, Schatz H. Vitre-ous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. J Clin Invest. 1993; 92:2620–2625.
   Google Scholar
• Robinson GS, Aiello LP. Angiogenic factors in dia-betic ocular disease: mechanisms of today, therapies for tomorrow. Int Ophthalmol Clin. 1998;38:89–102.
   PubMedGoogle Scholar
• Miller JW, Adamis AP, Aiello LP. Vascular endothe-lial growth factor in ocular neovascularization and pro-liferative diabetic retinopathy. Diabetes/Metabolism Revs. 1997;13:37–50.
   Google Scholar
• Boulton M, Gregor Z, McLeod D, Charteris D, Jarvis-Evans J, Moriarty P, Khaliq A, Foreman D, Allamby D, Bardsley B. Intravitreal growth factors in prolifera-tive diabetic retinopathy: correlation with neovascular activity and glycaemic management. Br J Ophthalmol. 1997;81:228–233.
   Google Scholar
• Khaliq A, Foreman D, Ahmed A, Weich H, Gregor Z, McLeod D, Boulton M. Increased expression of pla-centa growth factor in proliferative diabetic retinopa-thy. Lab Invest. 1998;78:109–116.
   Google Scholar
• Saghizadeh M, Khin HL, Bourdon MA, Kenney MC, Ljubimov AV. Novel splice variants of human tenascin- C mRNA identified in normal and bullous keratopathy corneas. Cornea 1998; 17:326–332.
   Google Scholar
• Ishiguro A, Spirin K, Shiohara M, Tobler A, Israel MA, Norton JD, Rigolet M, Shimbo T, Koeffler HP. Expression of Id2 and Id3 genes in human lympho-cytes. Leukemia Res. 1995;19: 989–996.
   Google Scholar
• Kenney MC, Chwa M, Opbroek AJ, Brown DJ. In-creased gelatinolytic activity in keratoconus keratocyte cultures. A correlation to an altered matrix metallopro-teinase-2/tissue inhibitor of metalloproteinase ratio. Cornea 1994;13: 114–124.
   Google Scholar
• Balza E, Siri A, Ponassi M, Caocci F, Linnala A, Virtanen I, Zardi L. Production and characterization of mono- clonal antibodies specific for different epitopes of hu-man tenascin. FEBS Lett. 1993;332:39–43.
   Google Scholar
• Sin A, Knduper V, Veirana N, Caocci F, Murphy G, Zardi L. Different susceptibility of small and large hu-man tenascin-C isoforms to degradation by matrix metalloproteinases. J Biol Chem. 1995;270:8650–8654.
   PubMed Web of Science ®Google Scholar
• Gerhardinger C, Brown LF, Roy S, Mizutani M, Zucker CL, Lorenzi M. Expression of vascular endothelial growth factor in the human retina and in nonproliferative diabetic retinopathy. Am J Pathol. 1998;152:1453–1462.
   PubMed Web of Science ®Google Scholar
• Tucker RP, Hammarback JA, Jenrath DA, Mackie EJ, Xu Y. Tenascin expression in the mouse: in situ local-ization and induction in vitro by bFGF. J Cell Sci. 1993;104:69–76.
   Google Scholar
• Sakai T, Kawakatsu H, Ohta M, Saito M. Tenascin induction in tenascin nonproducing carcinoma cell lines in vivo and by TGF-I31 in vitro. J Cell Physiol. 1994; 159:561–572.
   PubMed Web of Science ®Google Scholar
• LaFleur DW, Fagin JA, Forrester JS, Rubin SA, Sharifi BG. Cloning and characterization of alternatively spliced isoforms of rat tenascin. J Biol Chem. 1994;269:20757–20763.
   Google Scholar
• Chiquet-Ehrismann R, Hagios C, Schenk S. The com-plexity in regulating the expression of tenascins. BioEs-says 1995;17:873–878.
   Google Scholar
• Ju H, Dixon IM. Extracellular matrix and cardiovascu-lar diseases. Can J Cardiol. 1996;12:1259–1267.
   PubMed Web of Science ®Google Scholar
• Couchman JR, Beavan LA, McCarthy KJ. Glomerular matrix: synthesis, turnover and role in mesangial ex-pansion. Kidney Int. 1994;45:328–335.
   Google Scholar
• Yokoyama H, Deckert T. Central role of TGF-f3 in the pathogenesis of diabetic nephropathy and macrovascular complications: a hypothesis. Diabet Med. 1996;13:313–320.
   PubMed Web of Science ®Google Scholar
• Ljubimov AV, Saghizadeh M, Spirin KS, Khin HL, Lewin SL, Zardi L, Bourdon MA, Kenney MC. Expres-sion of tenascin-C splice variants in normal and bullous keratopathy human corneas. Invest Ophthalmol Vis Sci. 1998;39:1135–1142.
   PubMed Web of Science ®Google Scholar
• Bourdon MA, Wikstrand CJ, Furthmayr H, Matthews TJ, Bigner DD. Human mesenchymal extracellular ma-trix antigen defined by monoclonal antibody. Cancer Res. 1983;43:2796–2805.
   Google Scholar
• Erickson HP. Tenascin-C, tenascin-R and tenascin-X: a family of talented proteins in search of functions. Curr Opin Cell Biol. 1993;5:869–876.
   PubMed Web of Science ®Google Scholar
• Crossin KL. Tenascin: a multifunctional extracellular matrix protein with a restricted distribution in develop-ment and disease. J Cell Biochem. 1996;61:592–598.
   PubMed Web of Science ®Google Scholar
• Chiquet-Ehrismann R, Matsuoka Y, Hofer U, Spring J, Bernasconi C, Chiquet M. Tenascin variants: differen-tial binding to fibronectin and distinct distribution in cell cultures and tissues. Cell Regul. 1991;2:927–938.
   Google Scholar
• Deryugina El, Bourdon MA. Tenascin mediates human glioma cell migration and modulates cell migration on fibronectin. J Cell Sci. 1996;109:643–652.
   PubMed Web of Science ®Google Scholar
• Murphy-Ullrich JE, Lightner VA, Aukhil I, Yan YZ, Erickson HP, Hook M. Focal adhesion integrity is down-regulated by the alternatively spliced domain of human tenascin. J Cell Biol. 1991;115:1127–1136.
   Google Scholar
• Leprini A, Querze G, Zardi L. Tenascin isoforms: pos-sible targets for diagnosis and therapy of cancer and mechanisms regulating their expression. Perspect Dev Neurobiol. 1994;2:117–123.
   Google Scholar
• Canfield AE, Schor AM. Evidence that tenascin and thrombospondin-1 modulate sprouting of endothelial cells. J. Cell Sci. 1995;108:797–809.
   PubMed Web of Science ®Google Scholar
• Jallo GI, Friedlander DR, Kelly PJ, Wisoff JH, Grumet M, Zagzag D. Tenascin-C expression in the cyst wall and fluid of human brain tumors correlates with angio-genesis. Neurosurgery 1997;41:1052–1059.
   PubMed Web of Science ®Google Scholar
• Kostianovsky M, Alba Greco M, Cangiarella J, Zagzag D. Tenascin-C expression in ultrstructurally defined an-giogenic and vasculogenic lesions. Ultrastruct Pathol. 1997;21:537–544.
   PubMed Web of Science ®Google Scholar
• Zagzag D, Friedlander DR, Dosik j, Chikramane S, Chan W, Greco MA, Allen JC, Dorovini-Zis K, Grumet M. Tenascin-C expression by angiogenic vessels in human astrocytomas and by human brain endothelial cells in vitro. Cancer Res. 1996;56:182–189.
   Google Scholar
• Mardon HJ, Grant RP, Grant KE, Harris H. Fibronectin splice variants are differentially incorporated into the extracellular matrix of tumorigenic and non-tumorigenic hybrids between normal fibroblasts and sarcoma cells. J Cell Sci. 1993;104:783–792.
   PubMed Web of Science ®Google Scholar
• Kosmehl H, Berndt A, Katenkamp D. Molecular vari-ants of fibronectin and laminin: structure, physiologi-cal occurrence and histopathological aspects. Virchows Arch. 1996;429:311–322.
   Google Scholar
• Kornblihtt AR, Pesce CG, Alonso CR, Cramer P, Srebrow A, Werbajh S, Muro AF. The fibronectin gene as a model for splicing and transcription studies. FASEB J. 1996;10:248–257.
   Google Scholar
• Xia P, Culp LA. Adhesion activity in fibronectin's al-ternatively spliced domain EDa (EIIIA): complementarity to plasma fibronectin functions. Exp Cell Res. 1995;217:517–527.
   PubMed Web of Science ®Google Scholar
• Chen W, Culp LA. Adhesion mediated by fibronectin's alternatively spliced EDb (EIIIB) and its neighboring type III repeats. Exp Cell Res. 1996;223:9–19.
   PubMed Web of Science ®Google Scholar
• Manabe R, Ohe N, Maeda T, Fukuda T, Sekiguchi K. Modulation of cell-adhesive activity of fibronectin by the alternatively spliced EDA segment. J Cell Biol. 1997;139:295–307.
   Google Scholar
• Castellani P, Viale G, Dorcaratto A, Nicol° G, Kaczmarek J, Querze G, Zardi L. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer 1994;59:612–618.
   Google Scholar
• Karelina TV, Eisen AZ. Interstitial collagenase and the ED-B oncofetal domain of fibronectin are markers of angiogenesis in human skin tumors. Cancer Detect Prey. 1998;22:438–44.
   PubMedGoogle Scholar
• Malecaze F, Clamens S, Simorre-Pinatel V, Mathis A, Chollet P, Favard C, Bayard F, Plouet J. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in pro-liferative diabetic retinopathy. Arch Ophthalmol. 1994; 112:1476–1482.
   Google Scholar
• Boulton M, Foreman D, Williams G, McLeod D. VEGF localisation in diabetic retinopathy. Br J Ophthalmol. 1998;82:561–568.
   PubMed Web of Science ®Google Scholar
• Hata Y, Nakagawa K, Ishibashi T, Inomata H, Ueno H, Sueishi K. Hypoxia-induced expression of vascular en-dothelial growth factor by retinal glial cells promotes in vitro angiogenesis. Virchows Arch. 1995;426:479–486.
   PubMed Web of Science ®Google Scholar
• Sone H, Kawakami Y, Okuda Y, Kondo S, Hanatani M, Suzuki H, Yamashita K. Vascular endothelial growth factor is induced by long-term high glucose concentra-tion and up-regulated by acute glucose deprivation in cultured bovine retinal pigmented epithelial cells. Biochem Biophys Res Commun. 1996;221:193–198.
   Google Scholar
• Hirata C, Nakano K, Nakamura N, Kitagawa Y, Shigeta H, Hasegawa G, Ogata M, Ikeda T, Sawa H, Nakamura K, Ienaga K, Obayashi H, Kondo M. Advanced glycation end products induce expression of vascular endothelial growth factor by retinal Muller cells. Biochem Biophys Res Commun. 1997;236:712–715.
   Google Scholar
• Levy AP, Levy NS, Goldberg MA. Post-transcriptional regulation of vascular endothelial growth factor by hy-poxia. J Biol Chem. 1996;271:2746–2753.
   Google Scholar
• Pfeiffer A, Spranger J, Meyer-Schwickerath R, Schatz H. Growth factor alterations in advanced diabetic retino-pathy: a possible role of blood retina barrier break-down. Diabetes 1997;46(Suppl 2):526–530.
   Google Scholar
• Behzadian MA, Wang XL, Shabrawey M, Caldwell RB. Effects of hypoxia on glial cell expression of angio-genesis-regulating factors VEGF and TGF-P. Glia 1998; 24:216–225.
   PubMed Web of Science ®Google Scholar
• Ogata N, Yamamoto C, Miyashiro M, Yamada H, Matsushima M, Uyama M. Expression of transforming growth factor-J3 mRNA in experimental choroidal neovascularization. Curr Eye Res. 1997;16:9–18.
   PubMed Web of Science ®Google Scholar
• Ozaki H, Okamoto N, Ortega S, Chang M, Ozaki K, Sadda S, Vinores MA, Derevjanik N, Zack DJ, Basilico C, Campochiaro PA. Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal neovascularization. Am J Pathol. 1998;153:757–765.
   Google Scholar